| Title |
Development of small-molecule viral inhibitors targeting various stages of the life cycle of emerging and re-emerging viruses
|
|---|---|
| Published in |
Frontiers of Medicine, November 2017
|
| DOI | 10.1007/s11684-017-0589-5 |
| Pubmed ID | |
| Authors |
Xiaohuan Wang, Peng Zou, Fan Wu, Lu Lu, Shibo Jiang |
| Abstract |
In recent years, unexpected outbreaks of infectious diseases caused by emerging and re-emerging viruses have become more frequent, which is possibly due to environmental changes. These outbreaks result in the loss of life and economic hardship. Vaccines and therapeutics should be developed for the prevention and treatment of infectious diseases. In this review, we summarize and discuss the latest progress in the development of small-molecule viral inhibitors against highly pathogenic coronaviruses, including severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus, Ebola virus, and Zika virus. These viruses can interfere with the specific steps of viral life cycle by blocking the binding between virus and host cells, disrupting viral endocytosis, disturbing membrane fusion, and interrupting viral RNA replication and translation, thereby demonstrating potent therapeutic effect against various emerging and re-emerging viruses. We also discuss some general strategies for developing small-molecule viral inhibitors. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 87 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 87 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 15 | 17% |
| Student > Master | 12 | 14% |
| Student > Bachelor | 12 | 14% |
| Other | 9 | 10% |
| Student > Ph. D. Student | 8 | 9% |
| Other | 13 | 15% |
| Unknown | 18 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 18 | 21% |
| Medicine and Dentistry | 10 | 11% |
| Chemistry | 9 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 8% |
| Immunology and Microbiology | 4 | 5% |
| Other | 12 | 14% |
| Unknown | 27 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 November 2021.
All research outputs
#2,444,138
of 23,008,860 outputs
Outputs from Frontiers of Medicine
#30
of 351 outputs
Outputs of similar age
#56,872
of 438,098 outputs
Outputs of similar age from Frontiers of Medicine
#1
of 18 outputs
Altmetric has tracked 23,008,860 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 351 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 438,098 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.